Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk (NVO) CEO Lars Jørgensen isn't ... "I would say, as expected, because of its success in the market, Wegovy and Ozempic and Rybelsus were included in the next round of IRA negotiations.

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Novo Nordisk accounts for 34% of the global ... 2032 (as it is composed of the same semaglutide molecule as Ozempic and Rybelsus), and has had stellar uptake seemingly limited only by supply.